NCT05310305Unknown不适用
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
Lei Li1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2022年3月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Objective remission rate
研究概览
简要总结
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Aged 18 years or older
- •Confirmed of recurrent, metastatic, and persistent advanced cervical cancer
- •Confirmed of subtypes of cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma
- •Accepting radiotherapy with concurrent anti PD-1 therapy
- •With detailed follow-up outcomes
排除标准
- •Not meeting all of the inclusion criteria
结局指标
主要结局
Objective remission rate
时间窗: One year
Objective remission rate in one month after the end of radiotherapy
次要结局
- Progression-free survival(One year)
- Overall survival(One year)
- Severe adverse events(Two years)
研究者
Lei Li
Professor
Peking Union Medical College Hospital
研究点 (1)
Loading locations...
相似试验
招募中
2 期
PD-1 Combined With Intensity Modulated Radiation Therapy in the Treatment of Intermediate-risk Nasopharyngeal CarcinomaT2-3N0 or T1-2N1EBV-DNA≤4000 Copy/mlNasopharyngeal CarcinomaNCT05229315XIANG YANQUN45
Unknown
不适用
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort StudyCarcinoma, Non-Small-Cell LungImmune-Related Adverse EventsNCT04115410Sungkyunkwan University4,724
招募中
不适用
Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and RadiotherapyHNSCCUrothelial CarcinomaSquamous Cell Carcinoma of the SkinSmall Cell Bronchial CarcinomasEsophageal CancerRenal Cell CarcinomaNSCLCNCT04892849University of Erlangen-Nürnberg Medical School200
已完成
1 期
A Study of PDR001 in Combination With LCL161, Everolimus or PanobinostatColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell CarcinomaNCT02890069Novartis Pharmaceuticals298
进行中（未招募）
2 期
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II StudyMetastatic Nasopharyngeal CarcinomaChemotherapy EffectNCT04872582XIANG YANQUN33